Stockreport

ImmunityBio (IBRX) Faces FDA Warning, BTIG Stays Positive [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF on ImmunityBio, Inc. (NASDAQ:IBRX) with a price target of $13 after a recent regulatory action by the Food and Drug Administration (FDA). The FDA's Office of Prescript [Read more]